Form 4: TScan Therapeutics: 10% Owner Boosts Stake

Lynx1 Capital Management LP, a 10% owner and director, increased its beneficial ownership in TScan Therapeutics, Inc. through recent common stock purchases.

Summary

• Lynx1 Capital Management LP, a 10% owner and director of TScan Therapeutics, Inc. (TCRX), acquired additional common stock.
• On December 19, 2025, 80,069 shares were purchased at a weighted average price of $0.8989 per share.
• On December 22, 2025, 75,500 shares were purchased at $0.9 per share.
• On December 23, 2025, 6,232 shares were purchased at a weighted average price of $0.8989 per share.
• Following these transactions, the reporting persons beneficially own 8,019,148 shares of common stock indirectly.
• The shares are held directly by Lynx1 Master Fund LP and a managed account, with Lynx1 Capital Management LP serving as investment manager.
• Weston Nichols is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager.

Sentiment

Score: 7

Explanation: The sentiment is positive due to significant insider buying by a 10% owner and director, indicating strong confidence in the company's valuation and future prospects.

Positives

• A significant 10% owner and director, Lynx1 Capital Management LP, increased its stake in TScan Therapeutics, Inc. by purchasing 161,801 shares of common stock.
• Insider buying often signals confidence in the company's future prospects and valuation.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
• Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Industry Context

This Form 4 filing indicates an insider's increased confidence in TScan Therapeutics, Inc. within the biotechnology or pharmaceutical sector. While not directly detailing industry trends, such insider activity can be a positive signal for investors, suggesting that a knowledgeable party sees value in the company's current or future position relative to its peers.

Comparison to Industry Standards

• This filing reports insider trading activity, which is not directly comparable to industry-wide financial or operational benchmarks.
• However, significant insider buying, especially from a 10% owner and director, is generally viewed favorably across all industries as a sign of management's belief in the company's intrinsic value and future prospects, contrasting with a lack of such activity or insider selling seen in some underperforming companies.

Related Party Transactions

• The securities are held indirectly by Lynx1 Master Fund LP and a managed account, for which Lynx1 Capital Management LP serves as investment manager. Weston Nichols is the sole member of the general partner of the Investment Manager. This structure represents a standard arrangement for an investment manager and its funds, and the beneficial ownership is disclosed accordingly.

Stakeholder Impact

• Shareholders: May view the insider buying as a positive signal, potentially increasing confidence in the stock and its future performance.
• Management/Board: Reinforces alignment of interests between a significant owner/director and other shareholders.

Next Steps

• The Reporting Persons undertake to provide full information regarding the number of shares purchased at each separate price within the reported ranges upon request.

Key Dates

Recommendation

The significant insider buying by a 10% owner and director, Lynx1 Capital Management LP, suggests strong confidence in TScan Therapeutics' current valuation and future prospects. Such activity often precedes positive company developments or reflects a belief that the stock is undervalued. This insider conviction provides a compelling reason for investors to consider a 'buy' recommendation, aligning with the actions of a well-informed stakeholder.

Keywords

TScan Therapeutics, TCRX, Lynx1 Capital Management, Insider Buying, Form 4, Stock Purchase, Beneficial Ownership, Director, 10% Owner